You just read:

Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for Relapsing-Remitting Multiple Sclerosis

News provided by

Synthetic Biologics, Inc.

Apr 29, 2014, 03:45 ET